Surface-PASylation of ferritin to form stealth nanovehicles
enhances in vivo therapeutic performance of encapsulated
ellipticine

J 2020

Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine

TESAROVA, B., S. DOSTALOVA, V. SMIDOVA, Zita GOLIÁŠOVÁ, Z. SKUBALOVA et. al.

Základní údaje

Originální název

Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine

Autoři

TESAROVA, B. (203 Česká republika), S. DOSTALOVA (203 Česká republika), V. SMIDOVA (203 Česká republika), Zita GOLIÁŠOVÁ (203 Česká republika), Z. SKUBALOVA (203 Česká republika), H. MICHALKOVA (203 Česká republika), H. DAVID (203 Česká republika), P. MICHALEK (203 Česká republika), Hana POLANSKÁ (203 Česká republika, domácí), M. VACUOVICOVA (203 Česká republika), J. HACEK (203 Česká republika), T. ECKSCHLAGER (203 Česká republika), M. STIBOROVA (203 Česká republika), A. S. PIRES (620 Portugalsko), A. R. M. NEVES (620 Portugalsko), A. M. ABRANTES (620 Portugalsko), T. RODRIGUES (620 Portugalsko), P. MATAFOME (620 Portugalsko), M. F. BOTELHO (620 Portugalsko), P. TEIXEIRA (620 Portugalsko), F. MENDES (620 Portugalsko) a Z. HEGER (203 Česká republika, garant)

Vydání

APPLIED MATERIALS TODAY, AMSTERDAM, ELSEVIER SCIENCE BV, 2020, 2352-9407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30404 Biomaterials

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 10.041

Kód RIV

RIV/00216224:14110/20:00115972

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.apmt.2019.100501

UT WoS

000530652300014

Klíčová slova anglicky

Biocompatibility; Breast carcinoma; Cancer therapy; Ferritin; PASylation; PEGylation

Štítky

14110515, 14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 10. 2021 17:13, Mgr. Tereza Miškechová

Anotace

V originále

Surface functionalisations substantially influence the performance of drug delivery vehicles by improving their biocompatibility, selectivity and circulation in bloodstream. Herein, we present the study of in vitro and in vivo behaviour of a highly potent cytostatic alkaloid ellipticine (Elli) encapsulated in internal cavity of ferritin (FRT)-based nanocarrier (hereinafter referred to as FRTElli). In addition, FRTElli surface was functionalised with three different molecular coatings: two types of protective PAS peptides (10- or 20-residues lengths) with sequences comprising amino acids proline (P), alanine (A) and serine (S) (to form PAS-10-FRTElli or PAS-20-FRTElli, respectively), or polyethylene glycol (PEG-FRTElli). All three surface modifications of FRT disposed sufficient encapsulation efficiency of Elli with no premature cumulative release of cargo. Noteworthy, all tested surface modifications displayed beneficial effects on the in vitro biocompatibility. PAS-10-FRTElli exhibited markedly reduced uptake by macrophages compared to PAS-20-FRTElli, PEG-FRTElli or unmodified FRTElli. The exceptional properties of PAS-10-FRTElli were validated by an array of in vitro analyses including formation of protein corona, uptake efficiency or screenings of selectivity of cytotoxicity. In murine preclinical model bearing triple -negative breast cancer (MDA-MB-231) xenograft, compared to free Elli or FRTElli, PAS-10-FRTElli displayed enhanced accumulation of Elli within tumour tissue, while hampering the uptake of Elli into off-target tissues. Noteworthy, PAS-10-FRTElli led to decreased in vivo complement (C3) activation and protein corona formation. Taken together, presented in vivo results indicate that PAS-10-FRTElli represents a promising stealth platform for translation into clinical settings. (C) 2019 Elsevier Ltd. All rights reserved.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

Citovat

TESAROVA, B., S. DOSTALOVA, V. SMIDOVA, Zita GOLIÁŠOVÁ, Z. SKUBALOVA, H. MICHALKOVA, H. DAVID, P. MICHALEK, Hana POLANSKÁ, M. VACUOVICOVA, J. HACEK, T. ECKSCHLAGER, M. STIBOROVA, A. S. PIRES, A. R. M. NEVES, A. M. ABRANTES, T. RODRIGUES, P. MATAFOME, M. F. BOTELHO, P. TEIXEIRA, F. MENDES a Z. HEGER. Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine. APPLIED MATERIALS TODAY. AMSTERDAM: ELSEVIER SCIENCE BV, 2020, roč. 18, MAR 2020, s. 1-11. ISSN 2352-9407. Dostupné z: https://dx.doi.org/10.1016/j.apmt.2019.100501.

@article{1670256,
   author = {Tesarova, B. and Dostalova, S. and Smidova, V. and Goliášová, Zita and Skubalova, Z. and Michalkova, H. and David, H. and Michalek, P. and Polanská, Hana and Vacuovicova, M. and Hacek, J. and Eckschlager, T. and Stiborova, M. and Pires, A. S. and Neves, A. R. M. and Abrantes, A. M. and Rodrigues, T. and Matafome, P. and Botelho, M. F. and Teixeira, P. and Mendes, F. and Heger, Z.},
   article_location = {AMSTERDAM},
   article_number = {MAR 2020},
   doi = {http://dx.doi.org/10.1016/j.apmt.2019.100501},
   keywords = {Biocompatibility; Breast carcinoma; Cancer therapy; Ferritin; PASylation; PEGylation},
   language = {eng},
   issn = {2352-9407},
   journal = {APPLIED MATERIALS TODAY},
   title = {Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine},
   url = {https://www.sciencedirect.com/science/article/pii/S2352940719306201?via%3Dihub},
   volume = {18},
   year = {2020}
}

TY  - JOUR
ID  - 1670256
AU  - Tesarova, B. - Dostalova, S. - Smidova, V. - Goliášová, Zita - Skubalova, Z. - Michalkova, H. - David, H. - Michalek, P. - Polanská, Hana - Vacuovicova, M. - Hacek, J. - Eckschlager, T. - Stiborova, M. - Pires, A. S. - Neves, A. R. M. - Abrantes, A. M. - Rodrigues, T. - Matafome, P. - Botelho, M. F. - Teixeira, P. - Mendes, F. - Heger, Z.
PY  - 2020
TI  - Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine
JF  - APPLIED MATERIALS TODAY
VL  - 18
IS  - MAR 2020
SP  - 1-11
EP  - 1-11
PB  - ELSEVIER SCIENCE BV
SN  - 23529407
KW  - Biocompatibility
KW  - Breast carcinoma
KW  - Cancer therapy
KW  - Ferritin
KW  - PASylation
KW  - PEGylation
UR  - https://www.sciencedirect.com/science/article/pii/S2352940719306201?via%3Dihub
L2  - https://www.sciencedirect.com/science/article/pii/S2352940719306201?via%3Dihub
N2  - Surface functionalisations substantially influence the performance of drug delivery vehicles by improving their biocompatibility, selectivity and circulation in bloodstream. Herein, we present the study of in vitro and in vivo behaviour of a highly potent cytostatic alkaloid ellipticine (Elli) encapsulated in internal cavity of ferritin (FRT)-based nanocarrier (hereinafter referred to as FRTElli). In addition, FRTElli surface was functionalised with three different molecular coatings: two types of protective PAS peptides (10- or 20-residues lengths) with sequences comprising amino acids proline (P), alanine (A) and serine (S) (to form PAS-10-FRTElli or PAS-20-FRTElli, respectively), or polyethylene glycol (PEG-FRTElli). All three surface modifications of FRT disposed sufficient encapsulation efficiency of Elli with no premature cumulative release of cargo. Noteworthy, all tested surface modifications displayed beneficial effects on the in vitro biocompatibility. PAS-10-FRTElli exhibited markedly reduced uptake by macrophages compared to PAS-20-FRTElli, PEG-FRTElli or unmodified FRTElli. The exceptional properties of PAS-10-FRTElli were validated by an array of in vitro analyses including formation of protein corona, uptake efficiency or screenings of selectivity of cytotoxicity. In murine preclinical model bearing triple -negative breast cancer (MDA-MB-231) xenograft, compared to free Elli or FRTElli, PAS-10-FRTElli displayed enhanced accumulation of Elli within tumour tissue, while hampering the uptake of Elli into off-target tissues. Noteworthy, PAS-10-FRTElli led to decreased in vivo complement (C3) activation and protein corona formation. Taken together, presented in vivo results indicate that PAS-10-FRTElli represents a promising stealth platform for translation into clinical settings. (C) 2019 Elsevier Ltd. All rights reserved.
ER  -

TESAROVA, B., S. DOSTALOVA, V. SMIDOVA, Zita GOLIÁŠOVÁ, Z. SKUBALOVA, H. MICHALKOVA, H. DAVID, P. MICHALEK, Hana POLANSKÁ, M. VACUOVICOVA, J. HACEK, T. ECKSCHLAGER, M. STIBOROVA, A. S. PIRES, A. R. M. NEVES, A. M. ABRANTES, T. RODRIGUES, P. MATAFOME, M. F. BOTELHO, P. TEIXEIRA, F. MENDES a Z. HEGER. Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine. \textit{APPLIED MATERIALS TODAY}. AMSTERDAM: ELSEVIER SCIENCE BV, 2020, roč.~18, MAR 2020, s.~1-11. ISSN~2352-9407. Dostupné z: https://dx.doi.org/10.1016/j.apmt.2019.100501.

Podrobný výpis o publikaci